Sun Pharma inks pact to develop nervous system drugs
Advertisement
New Delhi: Sun Pharma has entered into an agreement with Israel's Weizmann Institute of Science and Spain's Health Research Institute of Santiago de Compostela to develop products for treating neurological diseases like brain stroke and glioblastoma, a lethal brain cancer.
Scientists at Weizmann Institute have developed a recombinant enzyme currently undergoing animal studies for indications of brain stroke and glioblastoma.
Further studies of this enzyme will be conducted at the Health Research Institute of Santiago de Compostela in Spain. Moreover, this enzyme may potentially be indicated for uses beyond these two brain diseases.
"As per the signed tripartite agreement, Sun Pharma will have the first right to develop these additional indications," the Mumbai-based company said in a statement.
Besides, Sun Pharma will have the exclusive option to conduct further development of the enzyme after completion of the pre-clinical studies, it added.
The company will have commercial rights to this product globally. It will also fund all future studies to be conducted on the enzyme, it said.
"We see our collaboration with world-renowned academic institutions like the Weizmann Institute of Science and the Health Research Institute of Santiago de Compostela enabling new projects on breakthrough products to address current unmet medical needs," Sun Pharma Senior Vice President Kirti Ganorkar said.
Scientists at Weizmann Institute have developed a recombinant enzyme currently undergoing animal studies for indications of brain stroke and glioblastoma.
Further studies of this enzyme will be conducted at the Health Research Institute of Santiago de Compostela in Spain. Moreover, this enzyme may potentially be indicated for uses beyond these two brain diseases.
"As per the signed tripartite agreement, Sun Pharma will have the first right to develop these additional indications," the Mumbai-based company said in a statement.
Besides, Sun Pharma will have the exclusive option to conduct further development of the enzyme after completion of the pre-clinical studies, it added.
The company will have commercial rights to this product globally. It will also fund all future studies to be conducted on the enzyme, it said.
"We see our collaboration with world-renowned academic institutions like the Weizmann Institute of Science and the Health Research Institute of Santiago de Compostela enabling new projects on breakthrough products to address current unmet medical needs," Sun Pharma Senior Vice President Kirti Ganorkar said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.